Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aurora Medbiochem
Suzhou, Jiangsu, Chinaauroramedbiochem.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aurora Medbiochem is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation small molecule drugs for the treatment of cancer and other serious diseases. The company utilizes a proprietary drug discovery engine to target high-value biological mechanisms, specifically focusing on the DNA damage response (DDR) and the RAS/MAPK signaling pathway. Its lead candidate, AMB-101, is a potent and selective USP1 inhibitor currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors. By integrating structural biology and medicinal chemistry, Aurora Medbiochem aims to provide transformative therapies for patients with unmet medical needs globally.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Aurora Medbiochem.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurora Medbiochem.